ARK Genomic Revolution ETF
ARKG
59 hedge funds and large institutions have $50.8M invested in ARK Genomic Revolution ETF in 2018 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 15 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 15
2% more funds holding
Funds holding: 58 → 59 (+1)
0.43% more ownership
Funds ownership: 19.37% → 19.8% (+0.43%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital inflows, than outflows
Capital inflows: $17.2M | Capital outflows: $17.8M
7% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arlington Capital Management
Arlington Heights,
Illinois
|
+$6.32M |
| 2 |
Carroll Financial Associates
Charlotte,
North Carolina
|
+$2.76M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.3M |
| 4 |
Jane Street
New York
|
+$1.27M |
| 5 |
Cetera Advisor Networks
El Segundo,
California
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Passport Capital
San Francisco,
California
|
-$3.34M |
| 2 |
Penserra Capital Management
Orinda,
California
|
-$2.36M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.8M |
| 4 |
Morgan Stanley
New York
|
-$1.49M |
| 5 |
LPL Financial
San Diego,
California
|
-$1.12M |
ARKG Hedge Fund Activity: Q4 2018 in Review
59 of the 4,504 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q4 2018, worth a combined $50.8M — down 22% from $65.4M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ARKG and 14 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 18 added.
The largest buyer was Arlington Capital Management, opening a new position worth an estimated $6.32M. The largest seller was Passport Capital, exiting entirely with an estimated $3.34M sold.
- 59 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q4 2018, up from 58 in Q3 2018.
- Funds reported $50.8M of ARK Genomic Revolution ETF stock for Q4 2018, down 22% quarter-over-quarter.
- 14 funds opened new ARK Genomic Revolution ETF positions in Q4 2018 and 15 closed out, a net change of -1 holder.
- The largest ARK Genomic Revolution ETF buyer in Q4 2018 was Arlington Capital Management, an estimated $6.32M added.
- The largest ARK Genomic Revolution ETF seller in Q4 2018 was Passport Capital, an estimated $3.34M sold.
Based on aggregated 13F filings for Q4 2018.